| Trial ID: | L6875 |
| Source ID: | NCT01606397
|
| Associated Drug: |
Placebo
|
| Title: |
A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: LY2409021
|
| Outcome Measures: |
Primary: Number of participants with one or more drug related adverse events (AEs) or any serious AEs, From first dose of study drug up to discharge (at least 28 days after last dose) | Secondary: Pharmacokinetics: Area under the concentration curve (AUC) of LY2409021, From first study drug dose to Day 28 post last dose|Pharmacokinetics: Maximum concentration (Cmax) of LY2409021, From first study drug dose to Day 28 post last dose|Change in fasting blood glucose level, From Day -1 to Day 28 of dosing|Change in incremental area under the curve (AUC) for glucose, From Day -1 to Day 28 of dosing|Change in homeostasis model assessment of beta cell function (HOMA-B), From baseline to Day 28|Change in fasting glucagon level, From Day -1 to Day 28 of dosing|Change in fasting insulin level, From Day -1 to Day 28 of dosing|Change in fasting C-peptide level, From Day -1 to Day 28 of dosing|Change in fasting glucagon-like peptide-1 (GLP-1) level, From Day -1 to Day 28 of dosing
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2008-03
|
| Completion Date: |
2008-11
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-25
|
| Locations: |
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Singapore, Singapore|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01606397
|
